Analysts expect Genomic Health (NASDAQ:GHDX) to announce sales of $88.76 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Genomic Health’s earnings, with the lowest sales estimate coming in at $88.18 million and the highest estimate coming in at $89.10 million. Genomic Health reported sales of $83.98 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.7%. The business is expected to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that Genomic Health will report full year sales of $88.76 million for the current financial year, with estimates ranging from $367.32 million to $377.60 million. For the next year, analysts expect that the company will report sales of $418.39 million per share, with estimates ranging from $406.85 million to $434.87 million. Zacks’ sales averages are an average based on a survey of analysts that follow Genomic Health.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Thursday, March 8th. The medical research company reported $0.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.01). Genomic Health had a negative return on equity of 0.83% and a negative net margin of 1.13%. The company had revenue of $87.50 million for the quarter, compared to analysts’ expectations of $88.96 million. During the same quarter last year, the company earned $0.04 EPS. Genomic Health’s revenue for the quarter was up 5.8% compared to the same quarter last year.
GHDX has been the subject of several research analyst reports. Zacks Investment Research cut Genomic Health from a “hold” rating to a “strong sell” rating in a research report on Friday, March 9th. Barclays reiterated a “sell” rating and issued a $28.00 price objective on shares of Genomic Health in a research report on Monday, January 8th. Canaccord Genuity reiterated a “buy” rating and issued a $42.00 price objective on shares of Genomic Health in a research report on Tuesday, January 16th. JPMorgan Chase cut Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective for the company. in a research report on Wednesday, December 13th. Finally, ValuEngine upgraded Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.67.
NASDAQ:GHDX traded down $0.81 during trading hours on Wednesday, hitting $30.48. The company’s stock had a trading volume of 155,926 shares, compared to its average volume of 200,038. The stock has a market capitalization of $1,105.30, a price-to-earnings ratio of 3,011.00 and a beta of 0.63. Genomic Health has a 52-week low of $26.54 and a 52-week high of $37.50.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $35.51, for a total value of $177,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider James J. Vaughn sold 3,004 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $34.09, for a total value of $102,406.36. The disclosure for this sale can be found here. Insiders sold 42,946 shares of company stock valued at $1,449,902 in the last quarter. 46.20% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of GHDX. Meeder Asset Management Inc. grew its holdings in Genomic Health by 120.7% in the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 1,619 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Genomic Health in the third quarter valued at $138,000. Jane Street Group LLC acquired a new stake in Genomic Health in the third quarter valued at $227,000. Teacher Retirement System of Texas acquired a new stake in Genomic Health in the fourth quarter valued at $242,000. Finally, Virtu Financial LLC acquired a new stake in Genomic Health in the fourth quarter valued at $261,000. 89.99% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Genomic Health (GHDX) Will Announce Quarterly Sales of $88.76 Million” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://ledgergazette.com/2018/04/17/zacks-brokerages-expect-genomic-health-ghdx-will-announce-quarterly-sales-of-88-76-million.html.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.